News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genmab A/S (GEN.CO) Announces Preliminary Safety and Efficacy Data for Daratumumab


12/12/2011 9:55:29 AM

COPENHAGEN, Denmark, Dec. 11, 2011 (GLOBE NEWSWIRE) --Genmab A/S (Copenhagen:GEN) announced today encouraging preliminary safety and efficacy data from the first Phase I/II clinical study of daratumumab (HuMax(r)-CD38) in multiple myeloma. A 49%, 55%, and 61% reduction in the serum M-component was observed in the three patients treated at the highest dose level examined so far (4 mg/kg of daratumumab). The serum M-component is an abnormal protein produced by the cancerous plasma cells and is a direct marker for tumor activity. Reduction in the serum M-component is a key factor for response evaluations in multiple myeloma. The observed level of reduction therefore indicates that daratumumab was clinically active in these multiple myeloma patients.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES